^
    Back
    Association details:
    Biomarker:KDR V297L
    Cancer:Colorectal Cancer
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Clin Cancer Res
    Title:

    Pharmacogenetic angiogenesis profiling for first-line bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer

    Excerpt:
    CXCR1 rs2234671 G>C, CXCR2 rs2230054 T>C, EGFR rs2227983 G>A and VEGFR-2 rs2305948 C>T were significantly associated with RR.
    Secondary therapy:
    oxaliplatin
    DOI:
    10.1158/1078-0432.CCR-11-1115